 T-DOC ® 5 French Clinical Study  
 
Confidential © 2017 LABORIE  
 
 
 
 
STUDY NUMBER:  
TDOC5Fr -PEDS -01 
 
STUDY NAME:  
T-DOC® 5 Fr Pediatric Clinical Investigation:  
A Pi[INVESTIGATOR_206670], Safety and Usability of a New 5 French 
Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects  
 
DOCUMENT : 
CLINICAL STUDY PROTOCOL  
 
NCT NUMBER:  
[STUDY_ID_REMOVED]  
 
DOCUMENT VERSION & DATE:  
Version 2.02  
June 26, 2018  
 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 1 of 47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 1 of 47 
 
CLINICAL STUDY PROTOCOL  
 
DEVICE:  
T-DOC® 5 French Air -Charged Vesical and Abdominal Urodynamic Catheters  
 
 
 
STUDY NUMBER:  
TDOC 5Fr-PEDS -01 
 
STUDY NAME:  
T-DOC® 5 Fr Pediatric Clinical Investigation:  
A Pi[INVESTIGATOR_206671], Safety and Usability  of a New  [ADDRESS_246503] s 
 
Version 2 .02 
June 26, 2018  
  
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 2 of 47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 2 of 47 
 
TDOC5Fr -PEDS -01 
T-DOC® 5 Fr Pediatric Clinical Investigation:  
A Pi[INVESTIGATOR_206670], Safety and Usability of a New [ADDRESS_246504]  
Mississauga, Ontario, Canada, L4V1X1  
[PHONE_4441]  Primary Monitor  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
  
 

T-DOC ® 5 French Clinical
Study ProtocolTDOC5Fr -
PEDS -01-PRVersion 2.02  Page 3 of 47 
Confidential © 2017 LABORIE Uncontrolled when printed Page 3 of 47 
TDOC5Fr -PEDS -01 
T-DOC® 5 Fr Pediatric Clinical Investigation:
A Pi[INVESTIGATOR_206670], Safety and Usability of a New 5 French Air -Charged 
Catheter for Performing Urodynamic Studies on Pediatric Subjects  
CLINICAL STUDY PROTOCOL   
PREPARED BY  [CONTACT_206686] : 
Job function : 
Signature  : 
[CONTACT_1782]:  
In signing the box below the approver signifies that they have reviewed the protocol and approve it on the basis that it meet s the following 
requirements  
1. The protocol is consistent with the clinical plan
2. Adequacy of sample size and appropriateness of proposed statistical analysis
3. Accuracy of device description, efficacy and performance characteristics
4. Biological safety of Investigational and control devices and their appropriateness for human use
5. Conforman ce to all applicable regulations
6. Adequacy in meeting business needs
CLINICAL STUDY PROTOCOL   
APPROVED BY  [CONTACT_206687]  

 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 4 of 47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 4 of 47 
 
TDOC5Fr -PEDS -01 
T-DOC® 5 Fr Pediatric Clinical Investigation:  
A Pi[INVESTIGATOR_206670], Safety and Usability of a New [ADDRESS_246505] s 
INVESTIGATOR(S)  
Principal Investigator   
 
 
 
  
 
 
 [INVESTIGATOR_206672](S)  
 
 
 
  
  
 
   
 
 
 
 
  
 
INSTITUTION(S) INVOLVED  
 
 
 
 
 
 
 
  
 
  
  
  
 
  

 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 5 of 47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 5 of 47 
 
  
 
 
 
 
  
 
  
 
TDOC5Fr -PEDS -01 
T-DOC® 5 Fr Pediatric Clinical Investigation:  
A Pi[INVESTIGATOR_206670], Safety and Usability of a New 5 French Air -Charged 
Catheter for Performing Urodynamic Studies on Pediatric Subjects  
 
“CONFIDENTIAL INFORMATION"  
Will mean all information provided by [CONTACT_206688] 
"CONFIDENTIA L" by [CONTACT_206689] p arty at the time of disclosure.  If such transmittal 
occurs orally, the transmitting party will promptly reduce such transmittal in writing, mark 
and identify it as confidential, and provide such recor d to the o ther party.   
Specifically excepted fr om this is all information that  
1. was previousl y known by [CONTACT_206690]  
2. is publicly disclosed except by [CONTACT_206691]'s receipt of such inform ation 
3. is rightfully received by [CONTACT_206692]  
4. is independently developed by [CONTACT_206693]  
5. is disclosed pursuant to any jud icial or government request, requirement or order, 
provided that the disclosing party takes reasonable steps to provide the other party with 
sufficient prior notice in order to allow the other party to contest such request, 
requirement or order.  
The recei ving party will not disclose CONFIDENTIAL INFORMATION without authorization 
from the disclosing party.  This provision shall remain in effect for five (5) years following 
completion of this study.  COMPANY shall be provided with subject  information as allo wed 

 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 6 of 47 
 
Confidential © [ADDRESS_246506] in an emergency .  I also agree to document all the required 
information as fully as I can.  
ACCEPTED BY  
[CONTACT_162858]   [INVESTIGATOR_206673] (  PRINT NAME  
[CONTACT_206725]          
 
 
 
 
 
 
 
 
 
 
 
 
 

 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 7 of 47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 7 of 47 
 
TDOC5Fr -PEDS -01 
T-DOC® 5 Fr Pediatric Clinical Investigation:  
A Pi[INVESTIGATOR_206670], Safety and Usability of a New [ADDRESS_246507] release  
Amendments  2.0 December 1, 
2017  - Section 6.1 (Study 
Design) updated to 
explain investigational 
device test results will be 
given back to referring 
physician  for test 
interpretation .  
- Section 3.3 (Rationale) 
removed obsolete 
sentence  from previous 
study design : “As 
mentioned in Section 3.2 
above, the performance of 
ACC is often compared to 
water -perfused and this 
will be addressed under 
the secondary objective of 
this study.”  SSRI feedback 
from  
IRB & document 
editing error  
 2.01  April 12 ,  
2018  - Administrative updates: 
Remove d  
from sponsor team . 
- Change d infusion 
transducer to optional  in 
page 26. 
- Corrected “ -DOC” to “T -
DOC” in page 30. Internal re -
structuring & 
spelling 
corrections  

 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 8 of 47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 8 of 47 
 
- Corrected page 32 
reference Section 4.5 
(does not exist) to Section 
4.4 
- Corrected spelling in 
page 42 from “soured” to 
“sourced”, page 44  from  
“stripend”  to “stipend” .  
- Updated Section 20 
(Referenced Documents ) 
to include  
forms.   
 2.02  June 26, 2018  - Fixed spelling mistakes  
(“bacteruria” to 
“bacteriuria”)  
- Formatted table of 
contents to remove wrong 
headings  
- Update d Section 10.5 
(Contact [CONTACT_7171] ) 
- Referred  to the Statistical 
Analysis Plan in Section 
12.6 (Analysis Plan)  Administrative 
changes  
 
This is a clinical research protocol for a pi[INVESTIGATOR_206674]. This study is conducted in 
accordance with the clinical protocol, Good Clinical Practice, and FDA 21 CFR Parts 50, 812 – 
Investigational Device Exemptions . This study is conducted in accordance with the ethical 
principles that have their o rigin in the Declaration of Helsinki . 
  

 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 9 of 47 
 
Confidential © [ADDRESS_246508] for Effectiveness  ................................ .............................  14 
2.3 Secondary Hypothesis  ................................ ................................ ...............................  14 
3 BACKGROUND  ................................ ................................ ................................ .....................  16 
3.1 Medical Device  ................................ ................................ ................................ ...........  16 
3.2 Prior Literature & Studies  ................................ ................................ ..........................  18 
3.3 Rationale  ................................ ................................ ................................ ....................  18 
4 STUDY OBJECTIVES  ................................ ................................ ................................ ..............  19 
4.1 Primary Objectives  ................................ ................................ ................................ ..... 19 
4.2 Secondary Objectives  ................................ ................................ ................................  19 
4.3 Exploratory Objectives  ................................ ................................ ...............................  19 
4.4 Assessment of Risks and Adverse Device Effects  ................................ ......................  20 
5 MEDICAL DEVICE  ................................ ................................ ................................ .................  20 
5.1 Description  ................................ ................................ ................................ .................  20 
5.2 Purpose & Use  ................................ ................................ ................................ ...........  21 
5.3 Summary of Non -Clinical Safety & Performance Data  ................................ ..............  [ADDRESS_246509] ION ................................ ................................ ................................ ............  24 
7.1 Inclusion Criteria  ................................ ................................ ................................ ........  24 
7.2 Exclusion Criteria  ................................ ................................ ................................ .......  25 
7.3 Vulnerable Populations  ................................ ................................ .............................  25 
7.4 Recruitment Plans  ................................ ................................ ................................ ...... 25 
7.5 Informed Consent Process  ................................ ................................ .........................  25 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 10 of 
47 
 
Confidential © [ADDRESS_246510] Withdrawal  ................................ ................................ ................................ ... 26 
7.7 Suspension or premature termination  ................................ ................................ ...... 26 
8 MANAGEMENT OF MEDICAL DEVICE  ................................ ................................ ..................  26 
8.1 Description  ................................ ................................ ................................ .................  26 
8.2 Regimen  ................................ ................................ ................................ .....................  27 
8.3 Assignment t o Groups  ................................ ................................ ...............................  27 
8.4 Preparation and Handling  ................................ ................................ ..........................  27 
8.5 Packaging and Labelling  ................................ ................................ .............................  28 
8.6 Device Accountability  ................................ ................................ ................................  28 
8.6.1 Laborie to Study Site:  ................................ ................................ ..............................  28 
8.6.2  Study Site Usage:  ................................ ................................ ................................ .... [ADDRESS_246511] SAFETY  ................................ ................................ ................................ ..................  31 
10.1  Definitions  ................................ ................................ ................................ ..................  31 
10.1.1  Adverse Events:  ................................ ................................ ...............................  [ADDRESS_246512]:  ................................ ................................ .....................  31 
10.1.3  Device Deficiency:  ................................ ................................ ............................  31 
10.1.4  Serious Adverse Event:  ................................ ................................ ....................  [ADDRESS_246513]:  ................................ .............................  [ADDRESS_246514] ([LOCATION_003]DE):  ................................ .. [ADDRESS_246515] Information  ................................ ................................ ................................ .. 32 
10.6  Follow -Up ................................ ................................ ................................ ...................  32 
11 STUDY PROCEDURE  ................................ ................................ ................................ .............  32 
11.1  Visit Schedule  ................................ ................................ ................................ .............  32 
11.2  Screening for Eligibility  ................................ ................................ ..............................  33 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 11 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 11 of 47 
 
11.3  Day 1 (Screening & Clinic Visit)  ................................ ................................ ..................  33 
11.4  Day 5 -7 (Follow -Up) ................................ ................................ ................................ ... 33 
11.5  End of Study (EOS)  ................................ ................................ ................................ ..... [ADDRESS_246516] for Discomfort/Pain  ................................ ...........  37 
12.3.2  Exploratory Data Collection regarding influencing factors on insertion depth
 38 
12.4  Sample Size Determination & Power  ................................ ................................ ........  39 
12.5  Randomization / Blinding  ................................ ................................ ..........................  39 
12.6  Analysis Plan  ................................ ................................ ................................ ..............  40 
12.7  Deviations  ................................ ................................ ................................ ..................  40 
12.8  Early Stoppi[INVESTIGATOR_007]  ................................ ................................ ................................ ............  40 
13 DATA HANDLING & RECORD KEEPI[INVESTIGATOR_1645]  ................................ ................................ ................  [ADDRESS_246517] Access  ................................ ................................ ................................ ..............  40 
13.2  Confi dentiality & Security  ................................ ................................ ..........................  40 
13.3  Data Handling  ................................ ................................ ................................ ............  41 
13.4  Case Report Form (CRF) & Source Documents  ................................ ..........................  [ADDRESS_246518] Stipends or Payments  ................................ ................................ ...................  44 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 12 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 12 of 47 
 
17.3  Committees  ................................ ................................ ................................ ................  44 
17.4  Study Timetable  ................................ ................................ ................................ .........  44 
18 ETHICS AND REGULATO RY APPROVAL  ................................ ................................ ................  44 
19 PUBLICATION POLICY  ................................ ................................ ................................ ..........  45 
20 REFERENCED DOCUMENTS  ................................ ................................ ................................ . 45 
20.1  Informed Consent Documents  ................................ ................................ ..................  45 
20.2  Investigator’s Brochure ................................ ................................ ..............................  45 
20.3  Case Report Forms:  ................................ ................................ ................................ .... [ADDRESS_246519] Symptoms  
T-DOC®  Commercial name [CONTACT_206726]-charged catheters  
T-DOC® 5 Fr  5 French version of the T -DOC® air -charged catheter  
UDS  Urodynamic s 
[LOCATION_003] [LOCATION_002] of America  
VUDS  Video Urodynamic s  
WFC  Water -Filled Catheter  
 
 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 13 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 13 of 47 
 
2 INTRODUCTION  
2.1 Clinical Study Summary  
Number of Sites  1 – 2  
Number of Subjects  A minimum of 10  male and 10 female subjects 12 years of age and 
younger, with an overall m inimum of 2 8, and maximum of 33 subjects  
Objective  The primary objective of this study is to gather clinical data as follows:  
 
• To confirm that the T-DOC ® [ADDRESS_246520] s 12 years of age and younger.  
 
The secondary objective of this study is to gather user feedback 
regarding  device performance as follows:  
• To evalu ate the following subjective measures using defined 
ordinal scales: ease of use, presence of artefacts, stability of 
the tracing, perceived time savings, ease of voiding around 
the catheter, presence of use errors, and overall satisfaction.  
Inclusion criteria  • Male and Female (Child ren, 12 years of age  and younger ) 
• Subject s who are scheduled and normally indicated for 
urodynamic testing, for any medically necessary reason as per 
physician  discretion .     
Exclusion criteria  • Subject s who suffer from bladder infections (not including 
subject s with asymptomatic bacter iuria)  
• Subject s with urethral strictures  
• Subjects  who require the use of a suprapubic catheter  
Anticipated Study duration  The proposed recruitment phase following site in itiation is 12 weeks 
(first subject  in to last subject  out).  
 
Subject s will come to the clinic for one visit, their urodynamic 
procedure, where data pertaining to the safety, efficacy and usability 
aspects of catheter will be collected.  
 
Test duration may  be slightly longer than a standard test while 
assessment of the study materials is being made, and so discomfort 
and inconvenience associated with an extended test duration may 
occur.  
Follow -up Subject  follow -up will occur [ADDRESS_246521].  
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 14 of 
47 
 
Confidential © [ADDRESS_246522] an option to continue recruitment until 
the maximum is reached, given recruitment does not exceed the 
allocated timeline.  There will be a site monitoring visit where the site 
will be  closed out.    
2.2 Primary Hypothesi s 
Clinicians  will rate the T -DOC® [ADDRESS_246523] 95% of enrolled pediatric subjects [ADDRESS_246524] cases found below. A questionnaire will be presented to the clinician where the 
clinicians response will be limited to two choices.  For example, for the question o f safety, 
the clinician may respond with yes (the device is safe) or no (the device is not safe).  
Accordingly, a binomial distribution function will be used to evaluate the clinical study 
results related to the primary hypothesis. Because the alternative hypotheses are 
directionally based, the null hypotheses will be accepted or rejected based on one -tailed 
tests. As described in section 4. 4 the sponsor team has established that subjects are 
subjected to no more than minimal risk since an IDE is not requir ed for this study, 
therefore sample size will be determined based on a desired 95% confidence with 90% 
reliability.  
 
2.2.[ADDRESS_246525] for Safety  
H0: Clinicians rate T -DOC® 5 Fr vesical and abdominal catheter as safe  for measuring 
urodynamic pressur e in 95% of enrolled pediatric subjects   
Hα: Clinicians rate T-DOC® 5 Fr vesical and abdominal catheter as safe for measuring 
urodynamic pressure in less than  95% of enrolled pediatric subjects  
2.2.[ADDRESS_246526] for Effectiveness  
H0: Clinicians rate T -DOC® 5 Fr vesical and abdominal catheter as effective  for 
measuring urodynamic pressure  in 95% of enrolled pediatric subjects  
Hα: Clinicians rate T -DOC® 5 Fr vesical and abdominal catheter as effective for 
measuring urodynamic pressure  in less than  95% of enrolled pediatric subjects  
 
2.[ADDRESS_246527] 80% of trained clinical users shall rate the T -DOC® 5 Fr catheter usability 
performance as 3 or better (on a scale of 1 -5) for the clinical user questionnaire, 
comparing their  experience with use of their currently used urodynamics catheter.  The 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 15 of 
47 
 
Confidential © [ADDRESS_246528] case will be used to evaluate clinical study results for the 
secondary hypothesis.  
H0: 80% of c linicians  or more  rate T -DOC® 5 Fr vesical and abdominal cathet er 
usability performance as 3 or better comparing their experience with use of their 
currently used urodynamics catheter .   
Hα: Less than 80% of clinicians  rate T -DOC® [ADDRESS_246529]. However, beca use the 
number of clinicians involved in the study is anticipated to be small ( ≤ 5), the results will 
be reported based on an 80% confidence and the calculated reliability permitted by [CONTACT_206694] (i.e., count of clinicians).  See secti ons 12.[ADDRESS_246530] 95% of subjects capable of providing feedback on a Visual Analogue Scale, will 
grade their discomfort/pain experienced duri ng the procedure utilizing the T-DOC® 5 Fr 
vesical and abdominal catheter  at of 5 or lower, on the Wong -Baker scale from 0 (“No 
Hurt”) to 10 (“Hurts worst”).  
A Wong -Baker scale from 0 (“No Hurt”) to 10 (“Hurts worst”)  will be presented to the 
subject . 
H0: 95% or more of subjects capable of providing feedback on a Visual Analogue 
Scale, will grade their discomfort/pain experienced  experience during the 
procedure utilizing the T-DOC® 5 Fr vesical and abdominal catheter  at 5 or lower, on 
the Wong -Baker scale from 0 (“No Hurt”) to 10 (“Hurts worst”).  
Hα: Less than 95% of subjects capable of providing feedback on a Visual Analogue 
Scale, will grade their discomfort/pain experienced  experience during the 
procedure utilizing the T-DOC® 5 Fr vesical and abdominal catheter  at 5 or lower, on 
the Wong -Baker scale from 0 (“No Hurt”) to 10 (“Hurts worst”).  
The subjects will be presented with copi[INVESTIGATOR_206675] -Baker scale from 0 (“No Hurt”) to 10 
(“Hurts worst”)  and asked to respond to the question s by [CONTACT_206695]5Fr -PEDS -01-CRF4 . Subjects will respond to the question on a 
scale of 1 through 10.  To enable the use of a binomial distribution function for data 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 16 of 
47 
 
Confidential © [ADDRESS_246531]. However, because the number of 
subjects capable of providing feedback on the Wo ng-Baker scale is anticipated to be 
limited (≤ 14), the results will be reported based on a 95% confidence and the calculated 
reliability permitted by [CONTACT_206696] (i.e., count of subjects capable of 
providing feedback on the Wong -Baker scale).  See sections 12.4 Exploratory Endpoint 
and 12.5 Sample Size Determination and Power for further details.  
  
3 BACKGROUND  
3.1 Medical  Device  
Urodynamic testing makes use of both an intravesical (bladder) and abdominal (rectal) 
catheter, the aim being to make precise pressure -volume measurements  in order to 
characterize LUT function, identify the causes for symptoms, and quantify related 
pathophysiological processes (Bauer  et al. , 2015) . UDS  is considered in children if the outcome 
of the test is likely to  affect treatment choice, or when a treatment does not lead to an 
intended outcome.  Also, UDS testing is considered when surgi cal interventions are planned 
(Bauer  et al. , 2015) .  Information is gleaned on storage function  (detrusor activity, sensation, 
compliance, and capacity) and  voiding function (outflow obstruction, flow pattern, detrusor  
contractility and sustainability). Abdominal pressure recordings via a small rectal balloon 
catheter are necessary to  accurately assess changes in abdomi nal pressure as reflected in  
intravesical pressure changes  (Bauer  et al. , 2015) .  
 
Initially, WFCs were the only urodynamic catheter technology available and only intrav esical 
pressure was assessed ( Perez & Webster, 1992).  However, with the demand for dif ferent ways 
to better assess LUT dysfunction, multiple catheters types have been  developed.  Currently, 
there are four different UDS catheter -based technologies available: WFC, ACC, microtip 
catheters, and fiberoptic catheters.  It is generally known that minimal tracings artefacts and 
non-physiological changes in pressure are desired for a reliable UDS tracing  (Couri et al., 2017).  
It has been noted that ACC are less likely to be influenced by [CONTACT_206697], thus decreasing the 
occurrence of artefacts (Cooper  et al. , 2011,  Gammie et al., 2014 ).  The Sponsor views this as a 
great advantage in the pediatric population as movement artefact can be a common issue 
affecting interpretation of the urodynamic tracing.  There are several other advantages and 
disadvantages of the ACC method but they will not  be discussed in this protocol.  
    
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 17 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 17 of 47 
 
The existing T-DOC® [ADDRESS_246532] introduced to the 
market in the early 2000s.  The design of which comprises a patent -protected catheter balloon 
charging mechan ism (US6447462/ EP1255485) facilitates the pressure transfer medium for 
recording urodynamic pressure and detection of urodynamic events.   The device is provided as 
a sterile, single (one -time) use catheter.   
 
 
 
 
  
 
 
 
 
 
The catheter s under review in this clinical investigation are a smaller , 5 French version  of the 
existing 7 Fr design , and are intended  for use on both pediatric and adult populations for 
measuring urodynamic pressures.    
The 5 Frenc h catheter configuration  under assessment will be  a combination of one both a 
vesical (bladder) and rectal catheter : a single sensor vesical (bladder) urodynamics catheter, 
and an abdominal (rectal)  urodynamics catheter .  
Table 1.  Dimensional cha nges and operational data comparison between 7 French and 5 French .  
 Existing T-DOC® 7 French  Proposed T -DOC® 5 French  
 
   
Pves Balloon Sensor Location  1” from the tip  0.78” from the tip  
Pabd Balloon Sensor Location  1” from the tip  0.78” from the tip  
   
Catheter Length  23.5”  23.5”  
Flow Rate Specification  Maximum 70mL/min  Maximum 50 mL/min  
Sensor Balloon Measurement 
Error  Maximum 4.0% of applied 
pressure at 0 – 250 cmH 20 
(system level)  Maximum 4.0% of applied 
pressure at 0 –  250 cmH 20 
(system level)*  
Operational Pressure Range  0 to 250 cmH 20 0 to 250 cmH 20 
*Design feasibility test results indicate <3% balloon measurement error  

 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 18 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 18 of 47 
 
 
3.2 Prior Literature & Studies  
The T -DOC® ACCs  have been regarded as simple to use, easy to insert, set -up, and zero  to 
atmospheric pressure  (Internal  Doc #PD-TR-151-01).  This has been supported by [CONTACT_206698] -charged catheters are gaining popularity due to t heir simple 
handling and set-up (Chapple , MacDiarmid & Patel, 2009 ).  Several studies have been published 
that examine the accuracy and behaviour of ACCs , both in non-clinical (Cooper  et al. , 2011, 
Couri et al., 2007 ), and clinical (Gammie et al., 2016, Digesu  et al. , 2014) settings .  The use of 
ACCs is often compared to other methods (water -perfused or microtip catheters) like in the 
literature by [CONTACT_206699]., Digesu et al . and Cooper et al. , however in this study we will not be 
collecting objective patient data comparing the performance of ACC s vs. WFCs  or any other 
method.  Since this is a new investigational device, there is no prior literature examining the 
safety and effectiveness of the T -DOC ® [ADDRESS_246533] ion 5 of the Investigator Brochure (TDOC5Fr -PEDS -01-IB) for a more detailed 
review of the available prior clinical literature.  
 
3.3 Rationale  
To the study s ponsors’ knowledge, previous pediatric data has not been published examining  
the safety , performance or usability of the T-DOC® air-charged  UDS catheter  technology  in the 
pediatric  population , therefore it is necessary to conduct this study in order to  collect this data.  
This study will involve collection of safety and performance  data, cli nical user feedback, the 
recording of optimal insertion depth among other metrics, which will feed into  use factors and 
product labelling.  
This is considered a pi[INVESTIGATOR_206676] a regula tory perspective.  A pi[INVESTIGATOR_206677]-clinical testing (see TDOC5Fr -PEDS -01-IB, Section 4) and the fact that this is not a new 
technology, nor new diagnostic technique.  UDS is a well -established technique in 
characterizi ng LUT function in children (Bauer  et al. , 2015) , and the technical performance of 
ACCs  has been proven to be suitable for UDS (Couri  et al. , 2017).   Finally, t here will be  no 
control arm, blinding , or treatment/intervention component to this study.  This is based on the 
trial design and the fact that this is a non -comparative study, inclusion of a sham or placebo is 
not feasible nor necessary, and the device under evaluation is not a treatment or intervention.   
Previous literature has indicated that older children and adolescents anatomically can tolerate a 
7 French urethral catheter , from approximately the age of 10 according to one expert  (Gray 
2012).  Therefore, for the purposes of our study and to be consistent with an FDA pediatric 
guidance (U.S.  Department of Health and Human Services, 2014) , our recruitment will focus on 
children 12 years of age and younger which will include the Pediatric Subgroups  ‘Child’ (ages 2 
to 12 years of age ), ‘Infant’ (>1 month to 2 years)  and ‘Newborn (neonate)’  (birt h to 1 month of 
age) where urodynamics is normally indicated .  It is recommended that in children born with 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 19 of 
47 
 
Confidential © [ADDRESS_246534], sacral angenesis, or an anorectal malformation, a 
baseline UDS should be obtained between 3 and 6 months o f age and routinely yearly 
thereafter if the child is at risk for a changing neurological lesion  (Drzewiecki & Bauer, 2015) . 
This establishes utility of performing UDS in these very young patients .  Utility in newborns 
suffering from myelomeningocele has a lso been studied in order to identify those at an early 
and increased risk of rapid structural deterioration of the urinary tract (Bauer et al.,  1984, Sidi, 
Dykstra & Gonzalez, 1986).   For the purposes of this study, decisions regarding timing for 
prescrib ing urodynamic testing will be at the discretion of the Investigators.  
 
4 STUDY OBJECTIVES  
4.1 Primary Objectives  
The primary objective of this pi[INVESTIGATOR_206678]:  
• To confirm that the T -DOC®  5Fr vesical and abdominal catheters are safe and effective 
for measuring urodynamic pressure in pediatric subject s 12 years of age and you nger . 
 
4.2 Secondary Objectives  
The secondary objective of this pi[INVESTIGATOR_206679]:  
• To evaluate the following subjective measures using defined ordinal scales : ease of use, 
ease of insertion, presence of artefacts, stability of the tracing, perceived time savings, 
ease of voiding around catheter, presence of use errors and overall satisfaction . 
 
4.[ADDRESS_246535] 
feedback from those able to communicate this feedback for exploring  whether the newly 
designed, smaller sized T -DOC® [ADDRESS_246536] of several factors (e.g., age, gender, weight, height) on 
optimal insertion depth of the T-DOC® 5 Fr ca theters . These data will be analysed to form a 
basis for suggesting further hypotheses for later research.  
  
 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 20 of 
47 
 
Confidential © [ADDRESS_246537] s to risks of urethral instrumentation which can  result in  
infection, urethral trauma and pain (Winters et al . 2012) .  Other  risks can include transient 
discomfort during or following the procedure, transient dysuria or bleeding (hematuria) 
following the procedure, or urinary tract infection occurs in 2 -4% of subject s (Chapple , 
MacDiarmid & Patel,  2009) .  Thus, the clinician must weigh the risks and benefits  as to whether 
the urodynamic test  offer s additional diagnostic value beyond symptom assessment, physical 
examination and other diagnostic testing (Winters et al. , 2012).    The risks of radiation exposure 
during VUDS  should also be weighed against the benefits , and explained to the subject  (or 
subject ’s guardian), however LABORIE does not manufacture  radiation -emitting devices and so 
we do not offer mitigation against these risks.    
In conclusion, the overall residual risks associated with the use of T -DOC® [ADDRESS_246538] s are subjected to no more than minimal risk since an IDE is not 
required for this study (Ref: TDOC5Fr -PEDS -01 - Risk Determination).  Lastly, UDS and VUDS are  
widely -performed  procedure s on pediatric subject s requiring specialized management for 
urinary i ncontinence /retention  problems , as recommended by [CONTACT_206700] ( Abrams et al., 2013 ), 
and is useful in characterizing LUT function, identifying causes of symptoms and quantifying 
related pathophysiological processes (Bauer  et al. , 2015 ). 
  
5 MEDICAL DEVICE  
5.1 Descri ption  
 
  The catheters used 
in this study will be design verified, sterilized and appropriately labelled before the  clinical 
investigation  can begin .    
The catheter device models to be evaluated as part of this study include:  
1. T-DOC 5 Fr v esical si ngle sensor catheter  (yellow)  
2. T-DOC 5 Fr a bdominal single sensor catheters (blue)  
  

 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 21 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 21 of 47 
 
Traceability of investigational study materials will be maintained via  the Inventory Control Log 
(Q905 -FRM -17). Traceability of non -investigational materials required for t he study will be 
maintained through sales order shipment tracking using the sponsor’s ERP system.  Any 
remaining investigational material stock after study close -out will be returned to the study 
sponsor at the sponsors’ expense.    
The T -DOC® 5 French catheters are manufactured using equivalent materials to the existing T -
DOC® catheters , and are verified biocompatible in 
accordance with the standards EN ISO [ZIP_CODE] -5 and -10 and -18 – Biological evaluation of 
medical  devices.   
None of the materials being used in this study contain biologically active substances or 
pharmacological agents.  
From a Regulatory standpoint, the following medical device classification rules apply  in Europe, 
the [LOCATION_002] and Canada, respectively :  
 
Product Classification Rule  
In Summary:  
For the European Union, Class IIa  
For the [LOCATION_002], Class II as per FDA  
For Canada, Class II  as per Health Canada Medical Device Regulations  
 
5.2 Purpose & U se 
Intended Use:  The Urodynamic Catheters are intended for measuring urodynamic pressures. 
The Urodynamic Catheters are intended to be connected to Urodynamic Analyzer systems using 
a reusable electronic cable.  
Indications for Use:  The Urodynamic Catheters  are sterile and intended for single use on adult 
and pediatric patient population r equiring urodynamic pressure monitoring through the 
measurement of bladder, vaginal, urethral and rectal pressures.   
NOTE: Recruitment of adult patients is not within the scope of this study.  Urodynamic pressure 
monitoring of v aginal and urethral pressure measurements is also not within the scope.   
 
5.3 Summary of Non -Clinical Safety & Performance Data  
The T -DOC® [ADDRESS_246539] 
meet all biocompatibility requirements for acute tissue contact[CONTACT_206701], Sensitization, and Irritation.   Furthermore, design verification studies will be 
undertaken to verify that Level 2 design requirements ar e met.  Please refer to the Investigator 
Brochure for further details.  

 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 22 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 22 of 47 
 
    
5.4 Summary of Clinical Safety and Performance Data  
Please refer to Section 5 of the Investigator Brochure (TDOC5Fr -PEDS -01-IB) for detailed review 
of relevant previous clinical safet y and performance data.  In all literature presented , the T -
DOC® air -charged catheters are safe and  effective for measuring urodynamic  pressures further 
justifying the study rationale.   
 
5.5 Risks and Benefits  
Please r efer also to  Section 4. 4 above (Assessment of Risks and Adverse Device Effects) , and 
Section 6 of the Investigator Brochure (TDOC5Fr -PEDS -01-IB). 
Risks to the subject  will be no greater than those of a standard urodynamics test.  Physicians 
are responsible for determining whether subjec ts are normally indicated , and who would 
benefit from urodynamic  testing  are eligible for recruitment into this study.  T here is no direct 
subject  benefit for participating other than to gather objective evidence of T-DOC® 5 French air-
charged catheter cli nical use.    
It is important to note t he American Urological Association (AUA) has identified two clear 
categories of subject s who may benefit from urodynamic  studies ( Winters et al ., 2012 ): (1) 
those in whom information beyond  that obtained by a history, physical examination and  basic 
tests is necessary in order to make an accurate  diagnosis and direct therapeutic decisions, and 
(2) those whose LUT condition may have the potential to  cause deleterious and irreversible 
effects on the upper  urinary tracts. Marked functional and anatomic  abnormalities can be 
present even in the absence of  concomitant proportionate symptoms, particularly in  subject s 
with neurologic disease.    
In conclusion, the overall residual risks associated with the use of T -DOC® [ADDRESS_246540] s are subjected to no more than minimal risk since an IDE is not 
requi red for this study (Ref: TDOC5Fr -PEDS -01 - Risk Determination).   Lastly, Urodynamics is 
already a widely performed procedure on pediatric subject s requiring specialized management 
for urinary incontinence issues, as recommended by [CONTACT_206700] ( Abrams et al., 2013), and is useful 
in characterizing LUT function, identifying causes of symptoms and quantifying related 
pathophysiological processes (Bauer  et al. , 2015).  
 
[ADDRESS_246541] s will undergo a 
conventional urodynamic study ( VUDS  or non -VUDS ) using the investigational device that will 
be conducted according to Good Urodynamic Practices (Rosier et al ., 2016).   There is no need 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 23 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 23 of 47 
 
for any repeat catheterization or urodynamics testing using an approved (non -investigational) 
urodynamics catheter.   Urodynamic test results using the investigational device will be provided 
back to the referring physician for test interpretation.  Given pos itive test results for the 
investigational device design verification and manufacturing process validation in accordance 
with ISO [ZIP_CODE], the sponsor has n o reason to suspect device safety and performance will be 
any different as compared to the currently m arketed T -DOC® 7 French catheter.    Therefore, to 
reiterate,  the urodynamics pressure data collected using the investigational device will be used 
in the referring physician’s test interpretation for each participant enrolled, unless there is 
reason to bel ieve the  test should be repeated.   This can happen under normal (non -
investigational) circumstances if the test was  inconclusive  (Abrams, 2006).   
Further s ubject  data collected will include age, medical history, height, weight , adverse events  
during or immediately following the test and 5-7 days  follow -up, catheter insertion depth etc., 
as objective evidence  on each patients CRF .  There will be no control arm, blinding, or 
treatment/intervention component to this study.   
In order to evaluate  prospective product claims, a usability questionnaire will also be 
completed (one per clinical user , defined as a n individual trained and certified to perform UDS ).   
The study aim is to enlist 5 clinical users across 1 -2 sites.  Five users will allow for 85% of use 
errors  to be detected  (U.S. Department of  Health and Human Services, 2016) .  A minimum of [ADDRESS_246542]  
flow -through:  
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 24 of 
47 
 
Confidential © [ADDRESS_246543]’s participation is one clinic visit to receive their already 
prescribed urodynamics test.   Once ethics board approval is received, site training and 
initiation is expected to take 1-[ADDRESS_246544]  SELECTION  
7.1 Inclusion Criteria  
• Male and Female (Child ren and i nfants , 12 years of age and younger)  
 
• Subjects  who are scheduled  and normally  indicated  for urodynamics testing, for any 
medically necessary reason as per the physician .     
 

 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 25 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 25 of 47 
 
7.2 Exclusion Criteria  
• Subjects  who suffer from bladder infections (not including subject s with asymptomatic 
bacter iuria)  
• Subjects  with urethral strictures  
• Subjects  who require the use of a suprapubic catheter  
 
7.[ADDRESS_246545] s will be taken into consideration.  
The major premise of this study is that the T -DOC® [ADDRESS_246546] s.  Recruitment will be monitored through scheduled meetings with the site co -
ordinator.  If the subjec t and legal guardian sign the informed consent, this will be treated as 
the point of enrolment.    
7.5 Informed Consent Process  
The Investigator (according to applicable regulatory requirements), or a person designated by  
[CONTACT_737], and under the Investi gator's responsib ility, should fully inform the subject  and 
parents/guardians of all pertinent aspects of th is clinical trial, including the written information 
giving a favourable  opi[INVESTIGATOR_1649] b y the IRB .  New information in regard to the study will be provided 
to the subject by [CONTACT_198991].  
Prior to a subject ’s participation in the clinical trial, the written Informed Consent Form should 
be signed, name [CONTACT_56535] [CONTACT_19578] ’s parent/guardian,  and by [CONTACT_206702].   Additionally, the subject ’s assent 
should be collected.   A copy of the signed and dated written Informed Consent Form & Assent 
will be provided to the subject /guardian .  The date of informed consent and assent should be 
recorded on the subject’s CRF.   
The Informed Consent Form  & Assent  used by [CONTACT_206703] 's 
informed consent must be reviewed and approved by [CONTACT_206704]/ favourable  opi[INVESTIGATOR_1649].  
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 26 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 26 of 47 
 
The In formed Consent process will follow the ethical procedures as outlined in 21 CFR Part 50 – 
Subpart D – Additional Safeguards for Children in Clinical Investigations.  The IRB will determine 
whether there is no more than minimal risk to the child in determin ing whether one or both 
parents must provide their consent.   Provisions will be made for soliciting assent of the child 
wherever possible.       
The study s ponsor does not foresee  any circumstances where emergency enrolment would 
occur due to the device indication (it is not used in emergency situations), and the fact that 
patients being recruited are attending their urodynamics appointment as a pre -scheduled visit.  
 
7.[ADDRESS_246547]’s 
participation (see below). The I nvestigator will notify the sponsor when a subject is withdrawn 
from the study (and if possible why), and this will be reco rded on the subject’s CRF.  Subjects  
who withdraw from the trial will be allowed to be replaced by [CONTACT_99419].   
 
7.7 Suspension or premature termination  
The study may be terminated prematurely if the Sponsor  or the Investigator feel that the 
equipment is not producing results as expected which could  be due to inappropriate operator 
handling or faulty equip ment.  The Investigator and/or s ponsor would determine termination 
by [CONTACT_206705] , design defects  or evidence of noncompliance, or serious 
and/or continuing noncompliance  which could affect any of subject  safety, device performance 
or integrity of study data .  
This study does not include blinding and so a process for accessing and unblind ing subjects and 
Investigators is not required.  
 
8 MANAGEMENT OF MEDICAL DEVICE  
8.1 Description  
The following devices and equipment will be required for each patient.  Those indicated by 
[CONTACT_206706]:  
• Laborie Urodynamics processor already in use  
• Computer/laptop with Laborie UDS -120 urodynamics software already loaded and in 
use by [CONTACT_25733]  
• Infusion transducer (optional ) 
• Uroflowmetry/Urocap device configured with the Urodynamics processor and computer 
for pressure -flow studies, already in use by [CONTACT_25733] (optional)  
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 27 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 27 of 47 
 
• T-DOC® transducer cables:  
o Pabd (blue ) – Abdominal channel reusable cable  
o Pves ( yellow ) – Bladder channel re usable cable  
• One (1) air -charged T -DOC®  [ADDRESS_246548]   
• One (1) air -charged T -DOC® [ADDRESS_246549]  
• EMG cable (optional component at the discretion of the site)  
• EMG pa tches (optional component at the discretion of the site)  
• Laborie Urodynamics pump tub ing infusion line per subject  (must be Laborie part 
number: TUB500)  
• 1000 mL beaker * (whatever is currently in use at the site)   
• One (1) sterile saline bag per subject * 
• One (1) bottle omniopaque / contrast fluid per subject  (VUDS only)* 
• Tape *  
• Lubricant * 
• Gloves * 
• Any other supplies deemed necessary for conducting a Urodynamic study * 
 
The study agreement will further specify the equipment and disposables that will be required 
and provided by [CONTACT_206707].  
8.2 Regimen  
N/A – there is no treatment regimen required as part of this study.  
 
8.[ADDRESS_246550] s will be stratified to male and female subjects  (defined as gender at 
birth) , and to ensure minimum enrolment targets are met.  This includes:  
• A minimum of 10 male subjects  
• A minimum of 10 female subjects  
 
8.4 Preparation and Handling  
The Urodynamics system and air -charged catheters will be prepared, and maintained by [CONTACT_24201].  Catheters should be stored between -25°C to +50°C.  
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 28 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 28 of 47 
 
 
8.5 Packaging and Labelling  
Investigational  device labelling will appear on all investigational materials under FDA 21 CRF 
Subp art 812.5.  A copy of the investigational label is shown the Investigator’s Brochure.   
 
8.[ADDRESS_246551] s CRF form.   
8.6.1 Laborie to Study Site:  
All investigational devices or equipment transferred between Laborie and the study site must 
be recorded through  the Inventory Control Form .  This includes postal deliveries and any 
deliveries made in person by [CONTACT_206707].  Any equipment or devices that are not used and are 
retu rned to Laborie must be recorded on the Inventory Control Log Template as well .  When 
the devices have been received by [CONTACT_206707],  it is their responsibility to ensure that all inventory 
both at Laborie and the study site correlate.   All investigational devi ce accountability will be 
recorded through  the Inventory Control Form .  
 
8.6.2 Study Site Usage:  
All devices used directly for testing subject samples must be recorded on the Inventory Control 
Form.  All devices used by [CONTACT_206708].  This in cludes any devices used for 
training or demonstration or any devices which are noted to be defective when opened.  
 
8.[ADDRESS_246552] Compliance Monitoring  
Not applicable in this study.  
 
9 ASSESSMENT OF INVESTIGATIONAL DEVICE  
 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 29 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 29 of 47 
 
9.1 Endpoints  
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  
Primary    
To confirm the T -DOC® 5Fr 
vesical and abdominal catheters 
as a safe and effective means of 
measuring urodynamic pressure 
in pediatric subjects 12 years of 
age and younger.  The primary endpoint will be 
measured by [CONTACT_206709].  The  clinician will indicate 
whether the T -DOC® [ADDRESS_246553] 
95% of patients enrolled.    Given the intended 
use of the device, 
and the fact that 
there is no single o r 
combination of 
objective measures 
generated from the 
urodynamics test 
that can establish the 
safety and 
effectiveness, it is 
justified to obtain 
clinician feedback via 
a binomial response 
whether the device 
was safe and/or 
effective for 
measuring 
urodyna mic 
pressure.   
Secondary    
To evaluate the usability of the 
device by [CONTACT_206710]: ease of use, ease of 
insertion, presence of artefacts, 
stability of the tracing, 
perceived time savings, ease of 
voiding around catheter, 
presence of use errors and 
overall satisfaction.  The usability performance 
endpoint will be captured in a 
questionnaire format.   At least 
80% of trained clinical users shall 
rate the T -DOC® 5 Fr performance 
as 3.0 or better (on a scale of 1 -5) 
on the study outcome 
questionnaire.  
 When evaluating the 
usability of a device, 
the Sponsor feels its 
appropriate to use a 
subjective ordinal 
scale response while 
evaluating human 
and device usability 
factors.    
Tertiary/Exploratory    
To explore whether the newly 
designed, smaller sized T -DOC® 
5 Fr catheters causes undue This exploratory endpoint will be 
measured by [CONTACT_206711] (within the ab ilities of Given the patient 
population, use of 
the Wong -Baker face 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 30 of 
47 
 
Confidential © [ADDRESS_246554] feedback regarding the 
discomfort and pain level, for 
those able to communicate such 
feedback  the child) regarding the level of 
discomfort and pain experienced 
during their Urodynamic test 
using the Wong -Baker visual 
analogue scale.   
95% of patients capable of 
providing feedback on a Visual 
Analogue Scale, will grade their 
discomfort/pa in at 5 or lower, on 
the Wong -Baker scale from 0 (“No 
Hurt”) to 10 (“Hurts worst”).  pain scale is a proven 
tool in evaluating 
pain ratings in 
children and can be 
used for children as 
young as 3 years  old 
(Hockenberry, Wilson 
& Rodgers, 2016).   
To explore the effect of several 
factors (e.g., age, gender, 
weight, height) on optimal 
insertion depth of the T-DOC® 5 
Fr catheters .  Subjects’ age, gender, weight, and 
height will be recorded on 
TDOC5Fr -PEDS -01-CRF1 . These 
data will be analysed to determine 
a subject stratification approach 
to be used in examining further 
hypotheses for later research  
regarding optimal insertion depth . The sponsor would 
like to collect this 
information, due to a 
lack of available 
published data.  
 
9.2 Methods of Assessment  
A T-DOC ® [ADDRESS_246555]’s case.  P atients capable of providing feedback regarding their level of 
discomfort experienced during the procedure with the T-DOC®  5Fr vesical and abdominal 
catheters  will be presented with copi[INVESTIGATOR_206680] -Baker scale from 0 (“No Hurt”) to 10 
(“Hurts worst”)  and asked questions by [CONTACT_206712]5Fr -PEDS -01-CRF4 . Subjects will respond to the question s on a scale of 1 through 10.   
All study outcome data captured will be compi[INVESTIGATOR_206681].    
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 31 of 
47 
 
Confidential © [ADDRESS_246556]  SAFETY  
10.1 Definitions  
10.1.1  Adverse Events:  
Any untoward medical occurrence in a subject, whether or not related to the investigational 
medical device.  
10.1.[ADDRESS_246557]:   
Any adverse event related to the use of a n investigation medical device.  
10.1.3  Device Deficiency :  
Inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety 
or performance  
10.1.4  Serious Adverse Event:  
An adverse event that:  
1. Led to a death;  
2. Led to a serious deterioration in health of a subject , user, or others that:  
a. Results in a life-threa tening  illness or injury;  
b. Results in a permanent impairment of a body structure or body function;  
c. Requires in subject  hospi[INVESTIGATOR_1081];  
d. Results in medical or surgical intervention to prevent life -threatening illne ss or 
injury or permanent impairment to body structure or a body function;  
3. Led to foetal  distress, foetal  death or a congenital abnormality/birth defect.  
10.1.[ADDRESS_246558]:  
Any serious adverse effect on health or safety or any life -threa tening problem or death caused 
by, or associated w ith, a device, if that effect, problem, or death was not previously identified in 
nature, severity, or degree of incidence in the investigation protocol or application, or any other 
unanticipated serious pr oblem associated with a device that relates to the rights, safety, or 
welfare of subjects.  
10.1.[ADDRESS_246559] ([LOCATION_003]DE):  
Serious adverse device effect which by [CONTACT_6073], incidence, severity or outcome has not been 
identified in the cur rent version of the risk analysis report.  
 
10.[ADDRESS_246560] ed on the CRF . 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 32 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 32 of 47 
 
10.3 Reporting  
All serious adverse events and unanticipated adverse device effects occurring during the 
investigation will be reported as soon as possible, but no later than 10 working days after the 
Investigator/Laborie first learns of the effect. This information will be submitted to 
Laborie/investigator and the IRB.  
 
10.[ADDRESS_246561]:  
 
 
 
 
 
10.[ADDRESS_246562] follow -up.   
 
11 STUDY PROCEDURE  
11.1 Visit Schedule  
Evaluation  Screening & Clinic Visit  Follow -up  
Day 1  Day 5-7 
Informed Consent  & Assent  X   
Inclusion Criteria  X   
Exclusion Criteria  X   
Record any Adverse Events  X X 

 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 33 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 33 of 47 
 
Questionnaire for Operator 
(once minimum [ADDRESS_246563] s 
completed)   X 
 
11.[ADDRESS_246564] ’s may be screened for eligibility for this study by [CONTACT_206713].  No 
special testing is required in order to determine eligibility.   
 
11.3 Day 1 (Screening & Clinic Visit)  
1. Determine if  the subject  is eligible for this study . 
2. Conduct Infor med Consent  and Assent  discussion with the subject  and guardian 
and sign where required.  
3. Collect medical history and record in case report form ( TDOC5Fr -PEDS -01-CRF2).  
4. Collect  and record  other patient details as required on TDOC5Fr -PEDS -01-CRF1 
[weight (l bs), height (‘,”), date of birth, sex, etc].  
5. Site personnel will explain what will happen during the urodynamics test to the 
subject/parent or caregiver.   
6. Site personnel will p repare urodynamics equipment, study  materials, other 
sterile disposables and su pplies as required for the urodynamic study  and r ecord 
catheter lot  number  information on TDOC5Fr -PEDS -01-CRF1 . 
7. Follow the investigational device instructions for use for placing the catheters.    
Record insertion depth once catheter is in place  on TDOC5Fr -PEDS -01-CRF1 .   
8. Conduct urodynamic study according to Good Urodynamic Practice 
recommendations, including regular cough checking to ensure good pressure 
transmission and  catheter positioning  wherever possible  (Rosier  et al.,  2016) .  
9. If within capabilities of the child, and if their condition allows, complete 
TDOC5Fr -PEDS -01-CRF4  – Subject Questionnaire .  
 
11.4 Day 5 -7 (Follow -Up) 
1. Site personnel will telephone the subject’s guardian/caregiver and inquire about 
any adverse events that occurr ed after Visit [ADDRESS_246565] the call details on the subjects’ CRF (TDOC5Fr -PEDS -01-CRF1).  
 
NOTE: If an adverse event occurs during this study, any follow -up intervention prescribed is at 
the discretion of the Investigator.  Each subject will be contact[INVESTIGATOR_530] [ADDRESS_246566] notify Laborie of the 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 34 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 34 of 47 
 
outcome o f the follow -up. This information should also be recorded on the subjet’s CRF 
(TDOC5Fr -PEDS -01-CRF1).  
 
11.5 End of Study  (EOS)  
At the conclusion of the urodynamics test, the subject  is no longer required to undergo any 
further study -related procedures , with the  exception of a 5 -7 day telephone follow -up. 
Once a clinical user has performed  a minimum of 3  urodynamic studies  and the related tasks 
under this protocol , they are then eligible to complete the Usability Questionnaire ( TDOC5Fr -
PEDS -01-CRF3 ).      
Once a site has completed its’ target recruitment, the sponsor (Laborie) will schedule a time to 
close -out the site, either in person or by [CONTACT_206714] 14.[ADDRESS_246567] by [CONTACT_4907].  Given this, the 
allowable Type I error (α) will be 5% (1 -confidence), such that the clinician will grade the device 
as being safe and effective for 95% of  subjects enrolled in this study.   Whereas the 
corresponding Type II error is estimated at 10% (reliability). As stated earlier, safety and 
effectiveness will be evaluated separately via the following sets of hypotheses:  
 
12.1.[ADDRESS_246568] for Safe ty 
H0: Clinicians rate T -DOC® 5 Fr vesical and abdominal catheter as safe for measuring 
urodynamic pressure in 95% of enrolled pediatric subjects  
Hα: Clinicians rate T -DOC® 5 Fr vesical and abdominal catheter as safe for measuring 
urodynamic pressure in less than  95% of enrolled pediatric subjects  
12.1.[ADDRESS_246569] for Effectiveness  
H0: Clinicians rate T -DOC® 5 Fr vesical and abdominal catheter as effective  for 
measuring urodynamic pressure  in 95% of enrolled pediatric subjects  
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 35 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 35 of 47 
 
Hα: Clinicians rate T -DOC® 5 Fr vesical and abdominal catheter as effective  for 
measuring urodynamic pressure in less than  95% of enrolled pediatric subjects  
In both cases, analysis of the clinical results will be performed as outlined below based on a 
binomial distribution.  In general, t he probability mass function of a binomial random 
variable  X is: 
f(x)= ((𝑛
𝑥)𝑝𝑥(1−𝑝)𝑛−𝑥) 
 
In this study , n represents the number of patients accepted into the trial ; x represents  the 
number of procedures for which clinicians rate the device as safe or effective (as the case may 
be); and p = 0.95 ( as stated in  the null hypothesis that 95% of the time clinicians rate the  devi ce 
as safe or effective as the case may be) .  
Because the alternative hypotheses are directionally based, the null hypotheses will be 
accepted or rejected based on one -tailed tests.  If the numbers of patients accepted into the 
trial is 28 as expected (see section 12 .2 Sample Size Determination & Power ), the test statistic, 
for both one -tailed tests with an α =.05,  will be:   
 
𝑃(𝑡𝑟𝑢𝑒  𝑋≤ 𝑥)= (28
𝑥)0.95𝑥(1−0.95)28−𝑥 ≤ 0.[ADDRESS_246570]  been  rated  
safe.   The actual  results  will be tabulated  based  on the actual  number  of patients  excepted  into the 
study.  
 
12.2 Secondary Endpoint  
To satisfy the secondary (usability) endpoint, a categorical respons e variable using a defined 
ordinal data scale will be used.  At least 80% of clinical users, who have performed three or 
more procedures with subject device, shall rate the T -DOC® 5 Fr catheter usability performance 
as 3.0 or better (on a scale of 1 -5) for the clinical user questionnaire, comparing their 
experience with use of their currently used urodynamics catheter. For this endpoint, eligible 
clinicians will respond to the question s on a scale of 1 through 5.  To enable analysis based on a 
Binomial D istributions, responses of 3, 4, or 5 will be tallied as a positive result while responses 
of 1 or 2 will be tallied as a negative result.  However, because the number of clinicians who 
perform three procedures or more with the T -DOC® 5 Fr vesical and abdo minal catheter during 
this study is anticipated to be small (≤ 5), the results will be reported based on the confidence  
of 95%  (based on the assumed minimal risk level described in section 4. 4) and the calculated 
reliability permitted by [CONTACT_206696] (i.e., count of eligible clinicians).  The 
following hypothesis test case will be used to evaluate clinical study results.  
 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 36 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 36 of 47 
 
H0: 80% of c linicians rate T -DOC® 5 Fr vesical and abdominal catheter usability 
performance as 3 or better compar ed to  their experience with their currently used 
urodynamics catheter .   
Hα: Less than 80% of clinicians  rate T -DOC® 5 Fr vesical and abdominal catheter 
usability performance as 3 or better compar ed to  their experience with their 
currently used urodynamics cathe ter.   
The probability mass function of a binomial random variable  X stated above will again be used 
to analyse the questionnaire data.  For the secondary endpoint, n represents the number of 
clinicians who performed three or more procedures with the T-DOC® 5 Fr vesical and abdominal 
catheter ; x represents  the number of procedures for which  the eligible  clinicians rate the device 
usability performance as 3 or better compar ed to  their experience  with their currently used 
urodynamics catheter ; and p = 0. 8 (as stated in  the null hypothesis that 80% of the time 
clinicians rate the  devi ce usability performance as 3 or better compar ed to  their experience 
with their currently used urodynamics catheter ).  
Again, because the alternative hypothesis is directionally based, the null hypotheses will be 
accepted or rejected based on a one -tailed test.  For example, i f the numbers of clinicians 
eligible to complete a questionnaire is 5, t he test statistic, for the one -tailed tests, with an α 
=.05  will be:   
P(true  X≤ 𝑥)= (5
𝑥)0.8𝑥(1−0.8)5−𝑥 ≤ .05 
 
Again,  if it is assumed  that 5 clinicians  respond  to the questionnaire,  the reliability  level  would  
be 55%  (see Section  12.5  Sample  Size Determination  and Power).  Solving  for 𝑥 based  on this 
assumption  would  then  result  in the null hypothesis  being  rejected  when  1 or fewer  clinicians  
rate the T-DOC®  5 Fr vesical  and abdominal  catheter  usability  performanc e as 3 or better  
compared  to their  experience  with  their  currently  used  urodynamics  catheter  and accepted  
when  2 or more  clinicians  rate the T-DOC®  5 Fr vesical  and abdominal  catheter  usability  
performance  as 3 or better  compared  to their  experience  with  their currently  used  urodynamics  
catheter.   
 
Alternatively,  a second  calculated  confidence  and reliability  level  combination  could  be 80%  
and 70%,  respectively,  based  on [ADDRESS_246571] statistic, for the one -
tailed tests, with an α  =0.2 (i.e., 1 -confidence level) will be:   
P(true  X≤ 𝑥)= (5
𝑥)0.8𝑥(1−0.8)5−𝑥 ≤ .2 
 
Solving  for 𝑥 would  result  in the null hypothesis  being  rejected  when  2 or fewer  clinicians  rate 
the T-DOC®  5 Fr vesical  and abdominal  catheter  usability  performance  as 3 or better  compared  
to their  experience  with  their  currently  used  urodynamics  catheter  and accepted  when  3 or 
more  clinicians  rate the T-DOC®  5 Fr vesical  and abdominal  catheter  usability  performance  as 3 
or better  compared  to their  experience  with  their  currently  used  urodynamics  catheter.  
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 37 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 37 of 47 
 
 
Due to the minimal  risk of the device  as stated  in section  4.4, the study  team  has opted  to use a 
combination  of levels  where  the confidence  level  is stated  as 95%  (i.e.,  α = 0.05),  and the 
reliability  (power)  of the test will be calculated,  though  it will likely  be significantly  reduced.    
 
The actual  results  will be tabulated  based  on the actual  number  of clinicians  who  respond  to 
the questionnaire.   
 
12.[ADDRESS_246572] for Discomfort/Pain  
To satisfy  the first exploratory  endpoint  (subject  experience),  a categorical  response  variable  
using  the Wong -Baker  scale  from  0 (“No  Hurt”)  to 10 (“Hurts  worst”)  will be used.   The stated  
exploratory  endpoint  is that 95%  of patients  capable  of providing  feedback  on a Visual  
Analogue  Scale,  will grade  their  discomfort/pain  of 5 or lower,  on the Wong -Baker  scale  from  0 
(“No  Hurt”)  to 10 (“Hurts  worst”).   To enable  analysis  based  on a Binomial  Distributions,  
responses  of 1, 2, 3, 4, or 5 will be tallied  as a positive  result  while responses  of 6, 7, 8, 9, or 10 
will be tallied  as a negative  result.  Additionally,  groupi[INVESTIGATOR_206682].   A confidence  level  of stated  as 95 % (i.e.,  α = 0.05)  has been  selected  based  on the 
risk determination  that no more  than  minimal  risk is foreseen  for the subject  by [CONTACT_206715]  (4.4 Assessment  of Risks  and Adverse  Device  Effects).   As stated  earlier,  the follow ing 
hypothesis  test case  will be used  to evaluate  the exploratory  clinical  study  results.  
 
H0: 95% or more of subjects capable of providing feedback on a Visual Analogue 
Scale, will grade their discomfort/pain experienced  experience during the 
procedure ut ilizing the T-DOC® 5 Fr vesical and abdominal catheter  at 5 or lower, on 
the Wong -Baker scale from 0 (“No Hurt”) to 10 (“Hurts worst”).  
Hα: Less than 95% of subjects capable of providing feedback on a Visual Analogue 
Scale, will grade their discomfort/pain  experienced  experience during the 
procedure utilizing the T-DOC® 5 Fr vesical and abdominal catheter  at 5 or lower, on 
the Wong -Baker scale from 0 (“No Hurt”) to 10 (“Hurts worst”).  
The subjects will be presented with copi[INVESTIGATOR_206675] -Baker scale from 0 (“ No Hurt”) to 10 
(“Hurts worst”)  and asked to respond to the question s by [CONTACT_206716]5Fr -PEDS -01-CRF4 . As with the previous endpoints, the alternative 
hypothesis is directionally based, therefore, the null hypothesis will be accepted or rejected 
based on a one -tailed test. Because the subjects range in age from 2 -12 years, the number of 
subjects capable of providing feedback on the Wong -Baker scale is anticipated to be limited ( ≤ 
14). Similar to the secondary hypothesis , the study  team  has opted  to use a combination  of 
levels  where  the confidence  level  is stated  as 95%  (i.e.,  α = 0.05) , and the reliability  (power)  of 
the test will be calculated,  based  on the sample  size achieved  (i.e., count of subjects capable of 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 38 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 38 of 47 
 
providing feedback on the Wong -Baker scale). See section 12.[ADDRESS_246573] ion of a binomial random variable  X as stated for the primary and 
secondary endpoints will again be used to analyse the subjects’ questionnaire data.  For the 
exploratory endpoint, n represents the number of subjects capable of providing feedback on 
the Won g-Baker scale ; x represents  the number of subjects who  rate their discomfort/pain 
experienced  during the procedure utilizing the T-DOC® 5 Fr vesical and abdominal catheter  at 5 
or lower on the Wong -Baker scale from 0 (“No Hurt”) to 10 (“Hurts worst”) ; and p = 0. 95 (as 
stated in  the null hypothesis that 95% of subjects capable of providing feedback on a Visual 
Analogue Scale, will grade their discomfort/pain experienced  experience during the procedure 
utilizing  the T-DOC® 5 Fr vesical and abdomi nal catheter  at 5 or lower ).  
Again, because the alternative hypothesis is directionally based, the null hypotheses will be 
accepted or rejected based on a one -tailed test.  For example, i f the numbers of subjects 
capable of responding to the questionnaire  is 10, t he test statistic, for the one -tailed tests, will 
be:  
P(true  X≤ 𝑥)= (14
𝑥)0.95𝑥(1−0.95)14−𝑥 ≤ 0.05 
 
Again,  if it is assumed  that 14 subjects  respond  to the questionnaire,  the reliability  level  would  
be approximately  80%  (see Section  12.5  Sample  Size Determination  and Power).  Solving  for 𝑥, 
with  the assumed  count  of subjects  would  result  in the null hypothesis  being  rejected  when  12 
or fewer  subjects capable of providing feedback on a Visual Analogue Scale, grade their 
discomfort/pain experienced  experience during the procedure utilizing the T-DOC® 5 Fr vesical 
and abdominal catheter  at 5 or lower, on the Wong -Baker scale from 0 (“No Hurt”) to 10 
(“Hurts worst”).    
The actual  results  will be tabulated  based  on the actual  number  of subjects  who  respond  to the 
questionnaire.   
 
12.3.[ADDRESS_246574] and 5 -7 days follow -up, catheter 
insertion depth will be collected as objective evidence on each patient’s CRF, where insertion 
depth is considered the response variable a nd assumed to be influenced by [CONTACT_547], age, height, 
weight and/or BMI.  Adverse event data will be factored into the assessment of the adequacy of 
the individual insertion depth used during the subject’s procedure.  
The collected data will be reported using  graphical tools for central tendency and dispersion of 
insertion depths based on gender, age, height, weight, and BMI.  The goal of reporting data in 
this manner is to facilitate the identification of a natural subject stratification approach f or use 
in later research  regarding optimal insertion depth .   
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 39 of 
47 
 
Confidential © [ADDRESS_246575] population is not being controlled for age, height, or 
weight, this study exploratory objective is being evaluated as a case -series observational study. 
Accordingly, sample size will not be pre -determined based on pre -ordained confidence and 
reliability statements.  
 
12.4 Sample Size Determination & Power  
Sample size calculations were  and will be performed in accordance with Binomial Distribution 
theory  (except for the second exploratory objective) , utilizing the following formula:   
𝑛=𝑙𝑛(1−𝑐𝑜𝑛𝑓𝑖𝑑𝑒𝑛𝑐𝑒  𝑙𝑒𝑣𝑒𝑙 )
𝑙𝑛(𝑟𝑒𝑙𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 ) 
Where n is the number of samples (e.g., patients, clinicians), and ln is natural log.  In the case of 
the primary endpoint, the desired confidence level and reliability have been stated as 95% and 
90% respectively. Hence the minimum required number of samples for  the primary endpoint is 
28 as shown below.  
𝑛=𝑙𝑛(1−0.95)
𝑙𝑛(0.90) = 28  
In addition, the study sponsor will allow up to 33 subjects  (20% additional)  during the allowable 
recruitment time period given the minimum recruitment goals are met (see Section 6.1 for and 
Section 7.1 for stratification and recruitment requirements).  The additional subjects will ensure 
that the desired confidence and reliability levels are met should any data or subjects be 
disqualified due to technical errors or if any subject requ ests to exit the study .   
In the case of the secondary endpoint, the confidence level has been stated to be 80% and the 
reliability statement will be calculated based on the actual number of clinicians who respond to 
the questionnaire. For instance, if 5 c linicians respond to the questionnaire, and an α = 0.20 
(i.e., (1 - confidence level)) is maintained, the reliability of this test will drop to approximately 
73%.  
In the case of the first exploratory endpoint, the confidence level has been stated to be 95%  
and the reliability statement will be calculated based on the actual number of subjects who 
respond to the questionnaire. For instance, if 14 subjects respond to the questionnaire, and an 
α = 0.05 (i.e., (1 - confidence level)) is maintained, the reliabili ty of this test would be 
approximately 80%.  
In all cases, test statistics will be calculated based on the actual number of samples achieved.  
 
12.5 Randomization / Blinding  
Randomization and/or blinding is not utilized in this study based on study design.  
 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 40 of 
47 
 
Confidential © [ADDRESS_246576] design meets the user requirements.   
There are  currently  no criteria for stoppi[INVESTIGATOR_206683], however 
please refer to Section 7.7 for details about suspension or premature termination.   
 
13 DATA HANDLING & RECORD KEEPI[INVESTIGATOR_1645]  
13.[ADDRESS_246577] Access  
The Investigator/Institution will permit trial -related monitoring, audits, IRB review, and 
regulatory inspections by [CONTACT_206717]/documents as needed.  
 
13.2 Confidentiality & Security  
All information disclosed or provided by [CONTACT_1034] (or any company/institution acting on 
their behalf), or produced during the study , including, but not limited to, the  Study  Protocol, 
the CRFs, the Instructions for Use and the results  obtained  during the course of the study , is 
confidential.  The Investigator or any person  under his/her authority a grees to undertake to 
keep confidential and not to disclose the  information to any third party without the prior 
written approval of the Sponsor.  
However, the submission of this Study  Protocol and other necessary documentation to the 
Ethics Committee ( IRB) is expressly permitted, the IRB members having the same obligation of 
confidentiality.  
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 41 of 
47 
 
Confidential © [ADDRESS_246578]  party's account.  
All data to Laborie will be confidential and all subject  identifiers will be blacked out before 
being sent to Laborie. Documents will be kept in a secure location and all digital information 
will be kept following HIPAA and local government regulations.  
 
13.[ADDRESS_246579] of individuals will be maintained who are authorized to make any changes to the data. 
Data will be reviewed by [CONTACT_1034] (outside of monitoring personnel), and requests for 
clarification and/or corrections will be made through the mo nitor. Once the review is 
conducted, the database will be considered clean and ready for analysis. Missing values will 
remain missing, i.e. no attempt will be made to input missing values and only observed values 
will be used in data analyses and presentat ions.  
 
13.4 Case Report Form (CRF) & Source Documents  
All study staff will be trained on the protocol requirements and questionnaire completion. It is 
the responsibility of the Investigator to maintain adequate and accurate questionnaires and 
CRFs designed by L aborie to record all observations and other data pertinent to the clinical 
investigation.  All questionnaires and CRFs should be completed in their entirety in a neat, 
legible manner to ensure accurate integration of data. Should a correction be made, the 
information to be modified must not be overwritten.  The corrected information will be 
transcribed by [CONTACT_206718].  Source document worksheets for 
recording data will be created as agreed upon by [CONTACT_206719].  Data from 
the source documents should be entered into the CRF after each subject ’s visit.  The 
anonymized urodynamic data files (DTA files) are requested by [CONTACT_206720], to 
confirm the quality of the tracing.  A unique subject cod e will  be assigned to each subject  based 
on the site number (100) and sequential subject number (i.e. 100 -001). The investigator is 
responsible for maintaining subject  identifying information.   CRF’s will be treated as source 
data in the event that the ori ginal information is entered in the CRF first (and no source  
document worksheet is utilized for that data point).   
 
13.[ADDRESS_246580] Retention  
An investigator or sponsor shall maintain the records required by 21 CFR Part 812.140 during 
the investigation and for a p eriod of 2 years after the latter of the following two dates: The date 
on which the investigation is terminated or completed, or the date that the records are no 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 42 of 
47 
 
Confidential © [ADDRESS_246581] of their location of the respective essential documents. 
If the Investigator's personal situation is such that archiving can no longer be ensured by  
[CONTACT_12552]/her, the Investigator shall inform the Sponsor and the relevant records shall be  transferred 
to a mutually agreed upon designee.  
 
13.[ADDRESS_246582] an 
The Investigator agrees to provide reliable and accurate data , and all information  requested by 
[CONTACT_4690] (with the help of any questionnaire, other appropriate  instrument s) in an 
attributable, legible, contemptuous, original, accurate, and com plete form  according to the 
instructions provided and to ensure direct access to source  documents to Sponsor 
representatives.  Any changes to the sour ced data shall be traceable and not obscure the 
original entry.  
The Sponsor of this Study  is responsible to Health Authorities for taking all  reasonable steps to 
ensure the proper conduct of this s tudy  protocol with regards to ethics,  protocol  compliance, 
integrity and validity of the data recorded on  the CRF and questionnaires . Thus, the main  duty 
of the Monitoring Team is to help the  Investigator and the Sponsor maintain a high level of 
ethical, scientific, technical and  regulatory qua lity in all aspects of the study .  
At regular intervals during the study , the site will be contact[INVESTIGATOR_530], through  monitoring visits, 
letters or telephone calls, by a representative of the Monitoring Team to  review study progress, 
Investigator and subject  compliance with study protocol requirements, and any emergent 
problems. During these monitoring visits, the follow ing, but not exhaustive list of points will be 
scrutinized with the Investigator: subject  informed consent, subject  recruitment and follow -up, 
Adverse Event documentation and reporting, outcome events documentation and reporting,  
Investigational Product  allocation, Investigational  Product accountability, and quality of data.  
 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 43 of 
47 
 
Confidential © [ADDRESS_246583] access to his/her study records 
for review, being understood that this personnel is bound by [CONTACT_56520], and as such 
will not disclose any personal identity or personal medical informatio n. 
 
The Investigator will make every effort to help with the performance of the inspections, giving 
access to all necessary facilities, data, and documents.  
 
As soon as the Investigator is notified of a future inspection by [CONTACT_56521], he will inform 
the Sponsor and authorize the Sponsor to participate in this inspection.  
 
The confidentiality of the data verified and the protection of the subject s should be respected 
during these inspections.  
  
Any result and information arising from the inspections by t he regulatory authorities will be 
immediately communicated by [CONTACT_67852]. The Investigator shall take 
appropriate measures required by [CONTACT_206721].  
 
[ADDRESS_246584] operating procedures.  Deviations will be reviewed and signed off by [CONTACT_456].  If 
deviations are obse rved/reported that significantly affect or have the potential to significantly 
affect human subject protection or reliability of the trial results, then LABORIE will conduct a 
root cause analysis and implement appropriate corrective and preventative action s. 
16 AMENDMENTS  
If there are any changes to the protocol during the application of the study or during the length 
of the clinical study in progress, the IRB will be notified for review.  During an ongoing study if 
an amendment is made to the protocol the ame nded protocol will be sent to the applicable 
institution within the timelines required.  The Investigator should not implement any deviation 
from, or changes to the clinical protocol without agreement by [CONTACT_206722] /favourable opi[INVESTIGATOR_206684], except when 
necessary to eliminate an immediate hazard(s) to a clinical study subject . In some instances, an 
amendment may require a change to the Informed Consent Form. The investigator must 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 44 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 44 of 47 
 
receive an IRB  approval/favourable opi[INVESTIGATOR_206685].  
 
[ADDRESS_246585] Stipends or Payments  
Subjects will be offered a $[ADDRESS_246586] 
of parking and/or meals required during their clinic visit.   
The Sponsor has covered this study by [CONTACT_206723]. The certificate of insurance evidencing the coverage, 
insurance company, policy number and the sum insured are provided in the Study’s File.  
17.3 Committees  
A Data Monitor Co mmittee will no t be utilized in this study based on the evaluation of the level 
of potential  risks.  
 
17.4 Study Timetable  
PROPOSED STUDY TIMELINE  TOTAL DURATION (WEEKS)  ACTUAL DATES  
PROPOSED START DATE (Planning)  8 JULY 10, 2017  
PROPOSED SITE TRAINING & INITIATION 
PHASE  1 NOVEMBER 20, 2017  
PROPOSED RECRUITMENT (1st subject  in 
to last subject  out) 12 - 14 NOVEMBER 27,  2017  
PROPOSED DATABASE LOCKOUT  4 MARCH 16, 2018  
PROPOSED STUDY REPORT 
COMPLETION  4 MARCH 30, 201 8 
TOTAL (WEEKS / MONTHS)  34 / 81/2  
ESTIMATED COMPLETION (QUARTER)  Q2 FY2018  APRIL [ADDRESS_246587] been obtained.  Any 
additional requirements imposed by [CONTACT_206724].  This study  will be conducted in 
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 45 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 45 of 47 
 
compliance with all international laws and  regulations, and nation al laws and regulations of the 
countries in which the usability study  is performed, as well as any applicable guidelines.   
 
19 PUBLICATION POLICY  
The results of the study may be submitted for publication, whether peer -reviewed or marketing 
materials. Publication rights and details are covered in the Investigator Agreement, there may 
be other authors involved in the creation of the publication.  
 
20 REFERENCED DOCUMENTS  
20.1 Informed Consent Documents  
- TDOC5Fr -PEDS -01-AF1 – Pediatric Assent Form  
- TDOC5Fr -PEDS -01-ICF1 – Informed Consent Form  
- TDOC5Fr -PEDS -01-AF3 - Pediatric Assent Form  
- TDOC5Fr -PEDS -01-ICF3 - Informed Consent Form   
- TDOC5Fr -PEDS -01-AF2 - Pediatric Assent Form    
- TDOC5Fr -PEDS -01-ICF2  - Informed Consent Form   
- TDOC 5Fr-PEDS -01-HA - HIPAA Authorization   
- TDOC5Fr -PEDS -01-HA - HIPAA Authorization  
20.2 Investigator ’s Brochure   
- TDOC5Fr -PEDS -01-IB T-DOC 5 French Investigator’s Brochure  
 
20.3 Case Report Forms:  
- TDOC5Fr -PEDS -01-CRF1  - Case Report Form 1  
- TDOC5Fr -PEDS -01-CRF2  - Case Report Form 2  
- TDOC5Fr -PEDS -01-CRF3  - Case Report Form 3  
- TDOC5Fr -PEDS -01-CRF4  - Case Report Form 4  
 
21 BIBLIOGRAPHY   
Abrams P. Urodynamics. Springer Science & Business Media; 2006. 3rd ed. p.287  
Abrams, P., Andersson K.E., Artibani W., Birder L., Bliss D., Brubaker L., Cardozo, L., Chapple, C., 
Cottenden, A., de Ridder D., Dmochowski R., Dumoulin C., Drake M., Fry C., Hanno P., 
Herschorn S., Kelleher C., Koelbl H., Khoury S., Madoff R., Maher C., Milsom I., Moore K.H., 
Moore K.N., Ne wman D., Nijman R., Rosier P., Staskin D., Thuroff J., Tubaro A., Vodusek D., 
Wein A. (2013) Recommendations of the International Scientific Committee: Evaluation 
and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence in 

 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 46 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 46 of 47 
 
Abram s P., Cardozo L., Khoury S., Wein A. (Eds.) Incontinence: 5th International 
Consultation on Incontinence, Paris, February 2012 . (pp. 1904 -1907 ). ICUD -EAU.  
Ami Sidi, A., Dykstra, D. D., & Gonzalez, R. (1986). The Value of Urodynamic Testing in the 
Management of Neonates with Myelodysplasia: A Prospective Study. The Journal of 
Urology , 135(1), 90 –93. https://doi.org/10.1016/S0022 -5347(17)[ZIP_CODE] -3 
Bauer, S. B., Nijman, R. J. M., Drzewiecki, B. A., Sillen, U., & Hoebeke, P. (2015). International 
Children’s Continence Society standardization report on urodynamic studies of the lower 
urinary tract in children. Neurourology and Urodynamics , n/a -n/a. 
https://doi.org/1 0.1002/nau.[ZIP_CODE]  
Bauer, S. B., Hallett, M., Khoshbin, S., Lebowitz, R. L., Winston, K. R., Gibson, S., … Retik, A. B. 
(1984). Predictive Value of Urodynamic Evaluation in Newborns With Myelodysplasia. 
JAMA , 252(5), 650 –652. https://doi.org/10.1001/jama.198 4.03350050038023  
Chapple, C. R., MacDiarmid, S. A., & Patel, A. (2009). Urodynamics Made Easy . Elsevier Health 
Sciences.  
Cooper, M. A., Fletter, P. C., Zaszczurynski, P. J., & Damaser, M. S. (2011). Comparison of air -
charged and water -filled urodynamic pre ssure measurement catheters. Neurourology and 
Urodynamics , 30(3), 329 –334. https://doi.org/10.1002/nau.[ZIP_CODE]  
Couri, B. M., Bitzos, S., Bhardwaj, D., Lockhart, E., Yue, A., & Gopi[INVESTIGATOR_007], I. (2017). Performance 
analysis of the T -DOC® air -charged catheters: An alternate technology for urodynamics. 
Neurourology and Urodynamics . https://doi.org/10.1002/nau.[ZIP_CODE]  
Digesu, G . A., Derpapas, A., Robshaw, P., Vijaya, G., Hendricken, C., & Khullar, V. (2014). Are the 
measurements of water -filled and air -charged catheters the same in urodynamics? 
International Urogynecology Journal , 25(1), 123 –130. https://doi.org/10.1007/s00192 -
013-2182 -z 
Drzewiecki B.A., Bauer S.B. (2015) Urodynamics in the pediatric patient in I. Franco, P. Austin, 
S.B. Bauer (Eds.) Pediatric Incontinence: Evaluation and Clinical Management (pp 91 -98). 
West Sussex, [LOCATION_006]: Wiley -Blackwell. Retrieved July 21, 2017, f rom 
http://www.wiley.com/WileyCDA/WileyTitle/productCd -[PHONE_4442].html  
Gammie, A., Clarkson, B., Constantinou, C., Damaser, M., Drinnan, M., Geleijnse, G., … (The 
International Continence Society Urodynamic Equipment Working Group). (2014). 
International continence society guidelines on urodynamic equipment performance. 
Neuro urology and Urodynamics , 33(4), 370 –379. https://doi.org/10.1002/nau.[ZIP_CODE]  
Gammie, A., Abrams, P., Bevan, W., Ellis -Jones, J., Gray, J., Hassine, A., … Hashim, H. (2016). 
Simultaneous in vivo comparison of water -filled and air -filled pressure measurement 
catheters: Implications for good urodynamic practice. Neurourology and Urodynamics , 
35(8), 926 –933. https://doi.org/10.1002/nau.[ZIP_CODE]  
Gray , M. (2012). Traces: making sense of urodynamics testing --part 13: pediatric urodynamics. 
Urologic Nursing , 32(5), 251–255, 274.  
Hockenberry, MJ. (2016) Pain Assessment and Management in Children in Hockenberry, M. J., 
Wilson, D., & Rodgers, C. C. ( Eds). Wong’s Essentials of Pediatric Nursing - E-Book . (p.114 -
117). Elsevier Health Sciences.   
Perez, L. M., & Webster, G.  D. (1992). The history of urodynamics. Neurourology and 
Urodynamics , 11(1), 1 –21. https://doi.org/10.1002/nau.[PHONE_4443]  
 T-DOC ® 5 French Clinical 
Study Protocol  TDOC5Fr -
PEDS -01-PR Version 2.02  Page 47 of 
47 
 
Confidential © 2017 LABORIE   Uncontrolled when printed  Page 47 of 47 
 
Rosier P .F.W.M. , Schaefer W ., Lose G ., Goldman H .B., Guralnick M ., Eustice S ., et al. 
International Continence Society Good Urodynamic Practices and Terms 2016: 
Urodynamics, uroflowmetry, cystometry, and pressure -flow study. Neurourol Urodynam. 
2016 Dec 1;n/a -n/a. 
U.S. Department of Health and Human Services Food and Drug Administration Center for 
Devices and Radiological Healt h, Office of Device Evaluation Center for Biologics Evaluation 
Research (2014) Premarket Assessment of Pediatric Medical Devices – Guidance for 
Industry and Food and Drug Administration Staff.  Retrieved July 21, 2017 from: 
https://www.fda.gov/RegulatoryInformation/Guidances/ucm089740.htm   
U.S. Department of Health and Human Services Food and Drug Administration Center for 
Devices and Radiological Health, Office of Device Eval uation Center for Biologics Evaluation 
Research (2016) Applying Human Factors and Usability Engineering to Medical Device – 
Guidance for Industry and Food and Drug Administration Staff.  Retrieved Aug 8, 2017 
from: https://www.fda.gov/RegulatoryInformation/Guidances/ucm089740.htm   
Winters, J. C., Dmochowski, R. R., Goldman, H. B., Herndon, C. D. A., Kobashi, K. C., Kraus, S. R., 
… Society of Urodynamics, Female Pelvic Medicine  & Urogenital Reconstruction. (2012). 
Urodynamic studies in adults: AUA/SUFU guideline. The Journal of Urology, 188([ADDRESS_246588]), 
2464 –2472. https://doi.org/10.1016/j.juro.2012.09.081  
Unpublished  References:   
. Urodynamic Clinical Testing.  Reference Doc#PD -TR-151-01 
